Trial · NCT03887624
Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.
NCT03887624, Early phase 1, Completed, Zhejiang University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression. Trials, record NCT03887624. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03887624
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.
- NCT number
- NCT03887624
- Status
- Completed
- Phases
- Early phase 1
- Enrollment
- 16 participants, actual
- Lead sponsor
- Zhejiang University
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- Ethosuximide, Placebo, Escitalopram
- First posted
- 2019-03-25
- Last updated
- 2025-06-18
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Montgomery and Asberg Depression Rating Scale(MADRS） score | baseline and 43 days | The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Usual cutoff points are: 0 to 6 - normal/symptom absent, 7 to 19 - mild depression, 20 to 34 - moderate depression, \>34 - severe depression. Changes of MADRS score at therapeutic visit point compare with baseline. |
| Secondary | Quick Inventory of Depressive Symptomatology-Self Report(QIDS-SR） score | baseline and 43 days | The QIDS-SR is a psychological questionnaire used by clinicians to measure 16 factors across 9 different criterion domains for major depression. It is scored by summing the highest response in each of a set of questions relating to sleep, weight and psychomotor symptoms and then adding the remaining items. Scores range from 0 to 27 which may then be categorised as indicating none \[0-5\], mild \[6-10\], moderate \[11-15\], severe \[16-20\] and very severe \[21-27\] depressive symptoms. Changes of QIDS-SR score at therapeutic visit point compare with baseline. |
| Secondary | Hamilton Anxiety Rating Scale(HAMA） score | baseline and 43 days | The HAMA is a psychological questionnaire used by clinicians to rate the severity of a patient's anxiety. Scores range from 0 to 56. A score of 17 or less indicates mild anxiety severity. A score from 18 to 24 indicates mild to moderate anxiety severity. Lastly, a score of 25 to 30 indicates a moderate to severe anxiety severity. Changes of HAMA score at therapeutic visit point compare with baseline. |
| Secondary | MADRS score | baseline and 43 days | Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. Changes of individual score of MADRS at therapeutic visit point compare with baseline. |
| Secondary | Young manic rating scale(YMRS） score | baseline and 43 days | The Young Mania Rating Scale (YMRS) is an eleven-item multiple choice diagnostic questionnaire which psychiatrists use to measure the severity of manic episodes in children and young adults. The scores from each question are added together to form a total score ranging from 0 to 60, with higher scores indicating a greater severity of symptoms. Extremely high scores increase the risk of the child having bipolar disorder by a factor of 9, while extremely low scores decrease the risk by a factor of 10. A score of 13 or higher indicates a potential case of mania or hypomania, while a score of 21 or above indicates a probable case. The average score for children with mania is 25, while the average score for children with hypomania is 20. Changes of YMRS score at therapeutic visit point compare with baseline. |
| Secondary | Efficiency after 2 and 4 weeks of treatment. | baseline, week 2 and week 4 | Efficiency means that the score of MADRS decreases by more than or equal to 50% compared with its baseline score. |
| Secondary | Remission rate after 2 and 4 weeks of treatment. | baseline, week 2 and week 4 | Remission means that the total score of MADRS is less than 10. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03887624
GET https://conductscience.org/api/trials/v1/NCT03887624/registered